{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:39:37Z","timestamp":1792586377706,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clinbiochem.2026.111180","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:18:30Z","timestamp":1786465110000},"page":"111180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Non-steroidal anti-inflammatory drugs and CYP2C9 \u2013 Impacts of genetics and phenoconversion on the risk of adverse effects"],"prefix":"10.1016","volume":"146","author":[{"given":"M.","family":"Cameron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Katzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lalonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tetreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2026.111180_bb0005","series-title":"Working Together to Better Understand, Prevent, and Manage Chronic Pain: What we Heard. A Report by the Canadina Pain Task Force","year":"2020"},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0010","series-title":"Chronic Pain","author":"Stretanski","year":"2025"},{"issue":"12","key":"10.1016\/j.clinbiochem.2026.111180_bb0015","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1016\/j.pain.2011.07.016","article-title":"The epidemiology of chronic pain in children and adolescents revisited: a systematic review","volume":"152","author":"King","year":"2011","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/j.pain.0000000000001732","article-title":"Long-term impact of adolescent chronic pain on young adult educational, vocational, and social outcomes","volume":"161","author":"Murray","year":"2020","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMp1109084","article-title":"Alleviating suffering 101--pain relief in the United States","volume":"366","author":"Pizzo","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111180_bb0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2036.2008.03905.x","article-title":"Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks","volume":"29","author":"Rostom","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.clinbiochem.2026.111180_bb0035","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard.2003.018531","article-title":"Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials","volume":"63","author":"Zhang","year":"2004","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111180_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0045","series-title":"Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)","author":"Ghlichloo","year":"2023"},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111180_bb0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cpt.794","article-title":"Cyclooxygenase inhibition: pain, inflammation, and the cardiovascular system","volume":"102","author":"Grosser","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2125.2001.00348.x","article-title":"Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients","volume":"52","author":"Rahme","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111180_bb0060","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/03602530903118729","article-title":"New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme","volume":"41","author":"Wang","year":"2009","journal-title":"Drug Metab. Rev."},{"issue":"5\u20136","key":"10.1016\/j.clinbiochem.2026.111180_bb0065","first-page":"284","article-title":"The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data","volume":"22","author":"Zhou","year":"2022","journal-title":"Pharm. J."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111180_bb0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future","volume":"25","author":"Ingelman-Sundberg","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111180_bb0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cpt.1654","article-title":"PharmVar and the landscape of Pharmacogenetic resources","volume":"107","author":"Gaedigk","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0085","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cpt.2321","article-title":"Pharmacogene variation consortium: a global resource and repository for Pharmacogene variation","volume":"110","author":"Gaedigk","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/jpm9030040","article-title":"Pharmacogenomic testing: clinical evidence and implementation challenges","volume":"9","author":"Hippman","year":"2019","journal-title":"J. Pers. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111180_bb0100","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jmoldx.2019.04.003","article-title":"Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of American pathologists","volume":"21","author":"Pratt","year":"2019","journal-title":"J. Mol. Diagn."},{"issue":"12","key":"10.1016\/j.clinbiochem.2026.111180_bb0105","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1124\/dmd.108.022970","article-title":"Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(\u2212)-ibuprofen hydroxylation in vitro","volume":"36","author":"Chang","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"11","key":"10.1016\/j.clinbiochem.2026.111180_bb0110","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0090-9556(24)15081-7","article-title":"Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s","volume":"28","author":"McGinnity","year":"2000","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clpt.2004.04.006","article-title":"Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms","volume":"76","author":"Garcia-Martin","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111180_bb0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/00498250902862705","article-title":"Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes","volume":"39","author":"Karazniewicz-Lada","year":"2009","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111180_bb0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1067\/mcp.2002.125726","article-title":"Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2","volume":"72","author":"Kirchheiner","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111180_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2008.07.004","article-title":"Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers","volume":"58","author":"Lopez-Rodriguez","year":"2008","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0135","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2007.05.025","article-title":"Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms","volume":"133","author":"Pilotto","year":"2007","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.clinbiochem.2026.111180_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/genes11111337","article-title":"Pharmacogenomics for primary care: an overview","volume":"11","author":"Rollinson","year":"2020","journal-title":"Genes (Basel)"},{"issue":"23","key":"10.1016\/j.clinbiochem.2026.111180_bb0145","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.2146\/ajhp160030","article-title":"Integrating pharmacogenomics into electronic health records with clinical decision support","volume":"73","author":"Hicks","year":"2016","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cpt.273","article-title":"Advancing pharmacogenomics as a component of precision medicine: how, where, and who?","volume":"99","author":"Johnson","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7573","key":"10.1016\/j.clinbiochem.2026.111180_bb0155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.clinbiochem.2026.111180_bb0160","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/phar.1481","article-title":"Emerging roles for pharmacists in clinical implementation of pharmacogenomics","volume":"34","author":"Owusu-Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers","volume":"55","author":"Dunnenberger","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/clpt.2010.260","article-title":"The emerging role of electronic medical records in pharmacogenomics","volume":"89","author":"Wilke","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111180_bb0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajmg.c.31391","article-title":"PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics","volume":"166C","author":"Hoffman","year":"2014","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111180_bb0180","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/17512433.2025.2568089","article-title":"Genotype-guided pharmacotherapy: the challenges of integrating pharmacogenomic testing into routine healthcare with a focus on experiences at a single site","volume":"18","author":"Cavallari","year":"2025","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111180_bb0185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2079","article-title":"A tutorial for pharmacogenomics implementation through end-to-end clinical decision support based on ten years of experience from PREDICT","volume":"109","author":"Liu","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FPC.0000000000000364","article-title":"Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell personalized medicine collaborative","volume":"29","author":"Zajic","year":"2019","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0195","first-page":"6623269","article-title":"Association of CYP2C9 *3 and CYP2C8 *3 non-functional alleles with ibuprofen-induced upper gastrointestinal toxicity in a Saudi patient","author":"Bagher","year":"2023","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.671835","article-title":"Genetic variants in PTGS1 and NOS3 genes increase the risk of upper gastrointestinal bleeding: a case-control study","volume":"12","author":"Forgerini","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0205","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine","volume":"79","author":"Shah","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111180_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092890","article-title":"Phenoconversion of cytochrome P450 metabolism: a systematic review","volume":"9","author":"Klomp","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111180_bb0215","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1503\/cmaj.120951","article-title":"Grapefruit-medication interactions: forbidden fruit or avoidable consequences?","volume":"185","author":"Bailey","year":"2013","journal-title":"CMAJ"},{"issue":"15","key":"10.1016\/j.clinbiochem.2026.111180_bb0220","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0225","article-title":"Assessment of physician's knowledge of potential drug-drug interactions: an online survey in China","volume":"8","author":"Yuan","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"issue":"21","key":"10.1016\/j.clinbiochem.2026.111180_bb0230","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1001\/archinte.163.21.2625","article-title":"Physicians\u2019 decisions to override computerized drug alerts in primary care","volume":"163","author":"Weingart","year":"2003","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0235","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1365-2125.2006.02698.x","article-title":"Which drugs cause preventable admissions to hospital? A systematic review","volume":"63","author":"Howard","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0240","first-page":"355","article-title":"Drug-drug-gene interactions and adverse drug reactions","volume":"20","author":"Malki","year":"2020","journal-title":"Pharm. J."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111180_bb0245","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12916-020-01827-z","article-title":"Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study","volume":"18","author":"Turner","year":"2020","journal-title":"BMC Med."},{"issue":"7","key":"10.1016\/j.clinbiochem.2026.111180_bb0250","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1055\/s-0040-1710592","article-title":"Risk of bleeding with exposure to warfarin and nonsteroidal anti-inflammatory drugs: a systematic review and Meta-analysis","volume":"120","author":"Villa Zapata","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0255","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update","volume":"102","author":"Johnson","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.clinbiochem.2026.111180_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080382","article-title":"Pharmacokinetic evaluation of metabolic drug interactions between Repaglinide and celecoxib by a bioanalytical HPLC method for their simultaneous determination with fluorescence detection","volume":"11","author":"Han","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0265","series-title":"Phenotype Frequencies","year":"2025"},{"issue":"7","key":"10.1016\/j.clinbiochem.2026.111180_bb0270","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/pgs-2017-0194","article-title":"Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6","volume":"18","author":"Bahar","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.clinbiochem.2026.111180_bb0275","doi-asserted-by":"crossref","first-page":"C417","DOI":"10.1111\/j.1750-3841.2007.00483.x","article-title":"Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins","volume":"72","author":"Girennavar","year":"2007","journal-title":"J. Food Sci."},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111180_bb0280","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0044-1790258","article-title":"Pharmacokinetic and pharmacodynamic interactions between food or herbal products and oral anticoagulants: evidence review, practical recommendations, and knowledge gaps","volume":"51","author":"Talasaz","year":"2025","journal-title":"Semin. Thromb. Hemost."},{"issue":"11","key":"10.1016\/j.clinbiochem.2026.111180_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165278","article-title":"A prospective study of alcohol consumption and smoking and the risk of major gastrointestinal bleeding in men","volume":"11","author":"Strate","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111180_bb0290","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1047-2797(00)00040-5","article-title":"The effect of alcohol abuse on the risk of NSAID-related gastrointestinal events","volume":"10","author":"Neutel","year":"2000","journal-title":"Ann. Epidemiol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0295","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4062\/biomolther.2020.108","article-title":"Ibuprofen increases the hepatotoxicity of ethanol through potentiating oxidative stress","volume":"29","author":"Kim","year":"2021","journal-title":"Biomol. Ther. (Seoul)"},{"issue":"47","key":"10.1016\/j.clinbiochem.2026.111180_bb0300","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.3748\/wjg.v11.i47.7450","article-title":"Increased susceptibility of ethanol-treated gastric mucosa to naproxen and its inhibition by DA-9601, an Artemisia asiatica extract","volume":"11","author":"Oh","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111180_bb0305","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1111\/j.1750-3841.2011.02155.x","article-title":"Potential risks resulting from fruit\/vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters","volume":"76","author":"Rodriguez-Fragoso","year":"2011","journal-title":"J. Food Sci."},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40780-017-0083-x","article-title":"Effect of health foods on cytochrome P450-mediated drug metabolism","volume":"3","author":"Sasaki","year":"2017","journal-title":"J. Pharm. Health Care Sci."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0315","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1271\/bbb.70511","article-title":"Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro","volume":"72","author":"Hidaka","year":"2008","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0320","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1756-0500-7-128","article-title":"Changes in serum cytokines in response to musculoskeletal surgical trauma","volume":"7","author":"Reikeras","year":"2014","journal-title":"BMC. Res. Notes"},{"issue":"4","key":"10.1016\/j.clinbiochem.2026.111180_bb0325","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Therapeutics, inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment","volume":"215","author":"Stanke-Labesque","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2026.111180_bb0335","doi-asserted-by":"crossref","first-page":"11137","DOI":"10.3389\/jpps.2023.11137","article-title":"Drug-disease interaction: clinical consequences of inflammation on drugs action and disposition","volume":"26","author":"Abdallah","year":"2023","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.clinbiochem.2026.111180_bb0340","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/dmd.114.061093","article-title":"Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine","volume":"43","author":"Shah","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.clinbiochem.2026.111180_bb0345","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/dmd.114.060962","article-title":"A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and HepaRG cells","volume":"43","author":"Klein","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.clinbiochem.2026.111180_bb0350","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/cpt.2146","article-title":"Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail","volume":"109","author":"Lenoir","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.clinbiochem.2026.111180_bb0355","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1124\/jpet.110.175075","article-title":"The ligands of estrogen receptor alpha regulate cytochrome P4502C9 (CYP2C9) expression","volume":"338","author":"Mwinyi","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.clinbiochem.2026.111180_bb0360","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/pgs.15.40","article-title":"Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers","volume":"16","author":"Ochoa","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.clinbiochem.2026.111180_bb0365","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/dmd.32.5.484","article-title":"The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype","volume":"32","author":"Sandberg","year":"2004","journal-title":"Drug Metab. Dispos."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991202600113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991202600113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:43:57Z","timestamp":1791812637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991202600113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":73,"alternative-id":["S000991202600113X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2026.111180","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-steroidal anti-inflammatory drugs and CYP2C9 \u2013 Impacts of genetics and phenoconversion on the risk of adverse effects","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2026.111180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111180"}}